5-Methyltetrahydrofolic acid
Based on 9 publication(s) in Google Scholar
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 134-35-0
- Formula: C20H25N7O6
- Molecular Weight:459.46
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Gut Microbial Metabolite Library
HY-L078
-
Microbial Metabolite Library
HY-L084
-
Lipid Metabolism Compound Library
HY-L091
-
Food-Sourced Compound Library
HY-L094
-
Human Metabolite Library
HY-L123
-
Animal-Sourced Natural Product Library
HY-L157
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Vitamin Compound Library
HY-L197
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactic Acid Metabolite Compound Library
HY-L250
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) 5-Methyltetrahydrofolic acid
More- Nucleic Acids Res. 2023 Jan 25;51(2):952-965. [Abstract]
- J Adv Res. 2026 Mar 5:S2090-1232(26)00188-8. [Abstract]
- J Transl Med. 2023 Jun 6;21(1):365. [Abstract]
- Int J Pharm. 2019 Feb 10:556:89-96. [Abstract]
- Appl Microbiol Biotechnol. 2024 Dec;108(1):1-15. [Abstract]
- Aquac Rep. 2025 Apr 15.
- J Pharm Pharmacol. 2019 Nov;71(11):1645-1654. [Abstract]
- J Pharm Biomed Anal. 2025 Oct 3:268:117178. [Abstract]
- bioRxiv. 2025 Nov 20.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
RT-PCR
-
WB
-
Bio/Physico-chemical Assay
-
Flow Cytometry
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
5-Methyltetrahydrofolic acid (0, 10, 50 and 100 μM; 24 h) increases the production of ET-1 in endothelial cells in a concentration-dependent manner[2]. 5-Methyltetrahydrofolic acid (100 μM; 24 h) inhibits the production of thiobarbituric acid reactive substances (TBARS) by HUVEC in the presence of low-density lipoprotein[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 134-35-0
-
Appearance Solid
-
Molecular Weight 459.46
-
Formula C20H25N7O6
-
Color Off-white to yellow
-
SMILES
O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(NCC2N(C)C3=C(NC(N)=NC3=O)NC2)C=C1)=O
-
Synonyms
5-Methyl THF; 5-MTHF
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
2023 Jan 25;51(2):952-965. PMID: 36620887
5-Methyltetrahydrofolic acid purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2023 Jan 25;51(2):952-965. [Abstract]
Thermogram of a representative ITC experiment of THF-II-loti62 binding to THF (top) and overlay of integrated fitted heat plots of THF-II-loti62 binding to THF, NPR, H4B, 7DG, folinic acid, 5-Methyltetrahydrofolic acid and 6-biopterin (bottom).
-
J Adv Res
A novel zebrafish model unveils folate deficiency disrupts embryonic development via p53-driven cell cycle arrest. [Abstract]2026 Mar 5:S2090-1232(26)00188-8. PMID: 41794221 -
J Transl Med
Mitochondrial folate pathway regulates myofibroblast differentiation and silica-induced pulmonary fibrosis. [Abstract]2023 Jun 6;21(1):365. PMID: 37280614
5-Methyltetrahydrofolic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Jun 6;21(1):365. [Abstract]
Gene expression levels in cells treated with 5-Methyltetrahydrofolic acid (50 μM, 12 h) and TGF-β1 as indicated were determined by RT-qPCR.
5-Methyltetrahydrofolic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Jun 6;21(1):365. [Abstract]
Lysates from cells treated with 5-Methyltetrahydrofolic acid (50 μM, 12 h) and TGF-β1 as indicated were analyzed by western blotting.
5-Methyltetrahydrofolic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Jun 6;21(1):365. [Abstract]
Concentration analysis of H2O2 and MDA in cells treated with 5-Methyltetrahydrofolic acid (50 μM, 12 h) and TGF-β1 as indicated.
5-Methyltetrahydrofolic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Jun 6;21(1):365. [Abstract]
Flow cytometry analysis of total intracellular ROS (DCF) and mitochondrial ROS (MitoSOX Red) in cells treated with 5-Methyltetrahydrofolic acid (50 μM, 12 h) and TGF-β1 as indicated.
-
Int J Pharm
A "Ship-in-a-Bottle" strategy to create folic acid nanoclusters inside the nanocages of γ-cyclodextrin metal-organic frameworks. [Abstract]2019 Feb 10:556:89-96. PMID: 30528633 -
Appl Microbiol Biotechnol
Role of folic acid in regulating gut microbiota and short-chain fatty acids based on an in vitro fermentation model. [Abstract]2024 Dec;108(1):1-15. PMID: 38175236 -
-
J Pharm Pharmacol
Folic acid and its metabolite codetermination for pharmacokinetics with circadian rhythms and evaluation of oral bioavailability. [Abstract]2019 Nov;71(11):1645-1654. PMID: 31435940 -
J Pharm Biomed Anal
A rapid LC-MS/MS method for the simultaneous quantification of 10 key folate cycle intermediates in human plasma. [Abstract]2025 Oct 3:268:117178. PMID: 41061512 -
Solvent & Solubility
DMSO : 83.33 mg/mL (181.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wright AJ, et al. Comparison of (6 S)-5-methyltetrahydrofolic acid v. folic acid as the reference folate in longer-term human dietary intervention studies assessing the relative bioavailability of natural food folates: comparative changes in folate status following a 16-week placebo-controlled study in healthy adults. Br J Nutr. 2010 Mar;103(5):724-9. [Content Brief]
[2]. Ronco, et al. "5-methyltetrahydrofolic acid stimulates endothelin-1 production in low density lipoprotein-treated human endothelial cells." Nutrition, Metabolism and Cardiovascular Diseases 17.3 (2007): 188-194. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1765 mL | 10.8823 mL | 21.7647 mL | 54.4117 mL |
| 5 mM | 0.4353 mL | 2.1765 mL | 4.3529 mL | 10.8823 mL | |
| 10 mM | 0.2176 mL | 1.0882 mL | 2.1765 mL | 5.4412 mL | |
| 15 mM | 0.1451 mL | 0.7255 mL | 1.4510 mL | 3.6274 mL | |
| 20 mM | 0.1088 mL | 0.5441 mL | 1.0882 mL | 2.7206 mL | |
| 25 mM | 0.0871 mL | 0.4353 mL | 0.8706 mL | 2.1765 mL | |
| 30 mM | 0.0725 mL | 0.3627 mL | 0.7255 mL | 1.8137 mL | |
| 40 mM | 0.0544 mL | 0.2721 mL | 0.5441 mL | 1.3603 mL | |
| 50 mM | 0.0435 mL | 0.2176 mL | 0.4353 mL | 1.0882 mL | |
| 60 mM | 0.0363 mL | 0.1814 mL | 0.3627 mL | 0.9069 mL | |
| 80 mM | 0.0272 mL | 0.1360 mL | 0.2721 mL | 0.6801 mL | |
| 100 mM | 0.0218 mL | 0.1088 mL | 0.2176 mL | 0.5441 mL |
Powered by Bioz